Close Menu
Home › Bioprognos Gets CE Mark for Lung Cancer Dx Algorithm

Bioprognos Gets CE Mark for Lung Cancer Dx Algorithm

Dec 20, 2016
|
staff reporter

NEW YORK (360Dx) – Spanish diagnostics firm Bioprognos announced yesterday that it has received CE marking for MBDAA for Lung Neoplasia Dx — an algorithm used in the diagnosis of lung cancer — clearing it for sale in the European Union.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  2. Local Coverage Determinations Roundup: Transplant Genomics, Opko Health

  3. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  4. Veracyte Exclusively Licenses NanoString Diagnostic Platform for Up to $60M

  5. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.